Is transient global amnesia a risk factor for amnestic mild cognitive impairment?

Journal of Neurology
Barbara BorroniA Padovani

Abstract

Transient Global Amnesia (TGA) is a common condition of unknown aetiology characterised by the abrupt onset of severe anterograde amnesia, which lasts less than 24 hours. Some authors have suggested that subclinical impairment of memory functions may persist for much longer, but neuropsychological assessment lasting years after TGA attack has not been performed so far. The aim of this study was to evaluate longterm cognitive functions in patients with a previous TGA episode. Fifty-five patients underwent a standardised neuropsychological assessment after at least one-year from the TGA attack, and were compared with 80 age-matched controls. TGA patients showed worse performances on tests evaluating verbal and nonverbal long-term memory and attention, with comparable global cognitive functions. By applying current criteria for amnestic Mild Cognitive Impairment (MCI-a) on TGA subjects, a group consisting of 18/55 (32.7%) MCI-a subjects was identified. There was no association between the presence of MCI-a and demographic variables, vascular risk factors, years since the TGA episode, or ApoE genotype. This study demonstrates that TGA appears to be a relatively benign syndrome although objective memory deficits fulfilling MCI-a cri...Continue Reading

Citations

Mar 14, 2012·Archives of Neurology·Jonathan Graff-Radford, Keith A Josephs
Jul 7, 2005·Journal of Neurology·Max NedelmannMarianne Dieterich
Jul 22, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·C AgostiA Padovani
Aug 22, 2006·International Journal of Clinical Practice·A J Larner
Jan 1, 2013·Case Reports in Neurology·Ivan MarinkovicEero Pekkonen
Jan 21, 2006·Applied Neuropsychology·Francesco Le PiraVincenzo Perciavalle
Oct 29, 2011·Neurologic Clinics·Gary Hunter
Nov 30, 2010·Cortex; a Journal Devoted to the Study of the Nervous System and Behavior·Audrey NoëlFrancis Eustache
May 12, 2009·Medicina clínica·Gabriel SalazarDaniel Olivera
Oct 7, 2006·Acta Neurologica Scandinavica·B Guillery-GirardF Eustache
Aug 3, 2005·Medical Hypotheses·Ole Solheim, Tora Skeidsvoll
Mar 15, 2015·Revue neurologique·P QuinetteF Viader
Dec 25, 2012·Journal of the Neurological Sciences·Johanna BuhrAchim Frese
Feb 11, 2015·Mayo Clinic Proceedings·Julieta E Arena, Alejandro A Rabinstein
Dec 29, 2013·International Journal of Epidemiology·William S KremenMichael J Lyons
Aug 31, 2016·Molecular Medicine Reports·Zhiyou CaiGuanghui Chen
Mar 8, 2020·BMC Neurology·Rebecca Tynas, Peter K Panegyres
Jan 9, 2013·Nature Reviews. Neurology·Thorsten Bartsch, Christopher Butler
Feb 24, 2021·NeuroImage. Clinical·Mandy PirlichDorothee Saur
Jun 16, 2021·Acta Neurologica Scandinavica·Jinseung KimKang Min Park
Jun 14, 2021·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Dong Ah LeeKang Min Park

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.